DU-176b, an oral, direct Factor Xa antagonist.
Daiichi Sankyo Inc (formerly Daiichi Seiyaku Co Ltd) is developing DU-176b, a direct, orally active Factor Xa inhibitor, as an anticoagulant for the potential treatment of cardiovascular indications, including venous and arterial thrombosis. By January 2005, phase II studies had begun in the US and Europe, and by March 2006, phase II studies had begun in Japan. Phase II trials for the prevention of thromboembolism were ongoing in mid 2007.
Hylek
Elaine
E
Boston University Medical Center, Department of Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118, USA. ehylek@bu.edu
D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006801:Humans; D010330:Patents as Topic; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000378:metabolism
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D015951:Factor Xa